A culprit behind brain tumor resistance to therapy

March 5, 2012

Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine.

Current therapy for glioblastoma, the most prevalent in adults, includes targeting a protein called VEGF, which promotes the growth of blood vessels to the tumor. Unfortunately, in most glioblastoma patients treated with anti-VEGF drugs, tumors return shortly after treatment.

Through an international collaboration, Jiri Bartek, Jeremy Rich, and colleagues now show that these recurring tumors express a perpetually activated form of the VEGF receptor. This active VEGF receptor drives growth of the tumor even when VEGF is blocked. Directly inhibiting the VEGF receptor, however, killed the tumors and extended the survival of tumor-bearing mice that were resistant to VEGF blockade.

These results suggest that blocking this active VEGF receptor may represent an alternative treatment option in glioblastoma cases where VEGF targeting has failed.

Explore further: High VEGF signaling score tied to lung cancer prognosis

More information: Hamerlik, P., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111424

Related Stories

High VEGF signaling score tied to lung cancer prognosis

February 22, 2012

(HealthDay) -- A high vascular endothelial growth factor (VEGF) signaling score correlates with good prognosis in patients with early squamous cell carcinoma (SCC) of the lung, according to a study published online Feb. 21 ...

Recommended for you

Dogs detect breast cancer from bandage: researchers

March 24, 2017

Dogs can sniff out cancer from a piece of cloth which had touched the breast of a woman with a tumour, researchers said Friday, announcing the results of an unusual, but promising, diagnostic trial.

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.